"A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA."
- Registry ID
- R2810-ONC-1788
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Study type
- INTERVENTIONAL
- Sponsor
- REGENERON PHARMACEUTICALS INC
- Start date
- 2021-12-22
- Last update
- 2019-07-29
Conditions
Related clinical trials
- A PHASE 1 FIRST-IN-HUMAN, OPEN-LABEL STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF ABBV-711 AS A MONOTHERAPY OR IN COMBINATION WITH BUDIGALIMAB (ABBV-181) IN ADULT SUBJECTS WITH ADVANCED SQUAMOUS TUMORS
- RANDOMIZED PHASE III TRIAL OF NEOADJUVANT IMMUNOTHERAPY WITH RESPONSE ADAPTED TREATMENT VERSUS STANDARD-OF-CARE TREATMENT FOR RESECTABLE STAGE
III/IV CUTANEOUS SQUAMOUS CELL CARCINOMA
- A PHASE 2/3, ADAPTIVE, RANDOMIZED, OPEN-LABEL, CLINICAL STUDY TO EVALUATE NEOADJUVANT
AND ADJUVANT V940 (MRNA-4157) IN COMBINATION WITH PEMBROLIZUMAB (MK-3475)
VERSUS STANDARD OF CARE, AND PEMBROLIZUMAB MONOTHERAPY IN PARTICIPANTS WITH
RESECTABLE LOCALLY ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA (LA CSCC)
(INTERPATH-007)
- NEOADJUVANT CHEMORADIOTHERAPY FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA VERSUS DEFINITIVE CHEMORADIOTHERAPY WITH SALVAGE SURGERY AS NEEDED(NEEDS TRIAL)
- A RANDOMIZED, CONTROLLED, OPEN-LABEL, PHASE 2 STUDY OF CEMIPLIMAB AS A SINGLE AGENT AND IN COMBINATION WITH RP1 IN PATIENTS WITH ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE PEMBROLIZUMAB VERSUS PLACEBO AS ADJUVANT THERAPY FOLLOWING SURGERY AND RADIATION IN PARTICIPANTS WITH HIGH-RISK LOCALLY ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA (LA CSCC) (KEYNOTE-630)
View on source registry